TolerogenixX was founded in 2016 by a group of physicians from the University of Heidelberg. The idea to develop an alternative to standard immunosuppression arose from the desire to no longer treat transplanted patients (Tx) and autoimmune patients (AI) with a broad, unspecific weakening of the natural defences of their body, but to eliminate the cause of the problem.
TolerogenixX will innovate immunosuppression with its newly developed MIC cell treatments.
MIC cell treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Tx and AI patients.
By 2025, TolerogenixX will have treated more than 25,000 patients and reached unicorn status with 3.5 billion € of sales.
TolerogenixX is a highly innovative start-up company that will contribute to the launch of a new era in medical treatment, the era of cell and gene therapy. We are an interdisciplinary team consisting of competent and highly committed experts. It is our clear ambition to be an accountable partner for investors, scientists, the medical community and authorities. We efficiently transform budget into values and facts. We have a clear vision and strategy and are committed to implementing them. We are highly visible and well regarded.